Progressing a non-antibiotic antimicrobial treatment for Bovine Mastitis towards market - PanaMast

Projektinformationen

PanaMast

ID Finanzhilfevereinbarung: 767456

DOI 10.3030/767456

Abgeschlossenes Projekt

EK-Unterschriftsdatum 9 Juni 2017

Startdatum 1 Juni 2017

Enddatum 30 November 2019

Finanziert unter

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Gesamtkosten € 3 549 237,75

EU-Beitrag € 2 484 466,43

Koordiniert durch

SLAINTE BEOGA TEORANTA
Ireland

Ziel

The world is facing an antibiotics crisis, with resistant bacteria rendering current treatments ineffective. Novel, effective solutions are urgently required for this $40bn global market. Westway Health (WWH) is based in Galway, Ireland, and is on track to become a leading veterinary antimicrobials company in the EU. It has developed an innovative, non-antibiotic technology, effective at killing all bacteria, including antibiotic-resistant bacteria like MRSA, while not inducing resistance. WWH’s lead product in development is PanaMastTM LC, a breakthrough treatment of bovine mastitis, the most economically important infectious disease affecting the dairy industry. PanaMastTM LC will represent a step change in the way that dairy farmers manage mastitis, which affects 30% of the herd annually. It will: 1. Be the world’s first non-antibiotic medicine for mastitis, offering superior clinical outcomes and significant financial gains to end-users (€150/case); 2. Reduce wastage of milk and culling of cows; (3) Improve profitability and environmental performance on European farms and dairy processing sites. The innovation directly addresses the major global problem of antibiotic resistance, while providing a sustainable animal health solution that supports production of safe and high quality food. The Phase 1 PanaMast project was successfully completed ahead of schedule and on budget. It allowed WWH to: 1. Develop a regulatory roadmap detailing all steps required to progress from current stage of development (TRL7) to first sale of commercial product (TRL8); 2. Develop a robust commercial exploitation plan for PanaMastTM LC in EU and global markets; 3. Establish key strategic relationships to assist commercialisation of PanaMastTM LC
The Phase 1 results underpin this proposed project. The Phase 2 activities (pre-commercialisation/product development/product launch and commercialisation) are designed to ensure market launch and sale of PanaMastTM LC in the EU at TRL8 by 2020

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › public health
• natural sciences › biological sciences › microbiology › bacteriology
• agricultural sciences › animal and dairy science › dairy
• medical and health sciences › health sciences › infectious diseases
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Schlüsselbegriffe

• mastitis antibiotics antibiotic replacements zero withdrawal antibiotic resistance

Programm/Programme

• H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
• H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy
• H2020-EU.3.2.1. - Sustainable agriculture and forestry
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet

Thema/Themen

• SMEInst-07-2016-2017 - Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri-food and bio-based sectors

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

SLAINTE BEOGA TEORANTA

• Netto-EU-Beitrag: € 2 484 466,43
• Adresse: UNIT 204 BUSINESS INNOVATION CENTRE NUIG NEWCASTLE ; H91 Galway ; Irland
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ireland › Eastern and Midland › Dublin
• Region: Ireland › Eastern and Midland › Dublin
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 3 549 237,75